| Previous Close | 0.9200 |
| Open | 0.9100 |
| Bid | 0.8800 x 0 |
| Ask | 0.9100 x 0 |
| Day's Range | 0.8800 - 0.9200 |
| 52 Week Range | 0.5600 - 1.5200 |
| Volume | 58,332 |
| Avg. Volume | 60,813 |
| Market Cap | 210.114M |
| Beta (5Y Monthly) | 0.30 |
| PE Ratio (TTM) | 62.86 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Resverlogix Announces US$6 Million Debenture Financing
CALGARY, Alberta, May 05, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has entered into an investment agreement with a subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (“Hepalink”) which provides for Hepalink to purchase 10% secured convertible debentures of the Company in the aggregate principal amount of US$6 million (the “Debentures”) for a purchase price equal to the principal amount of the Debentures (the “Debenture Financing”). The Debentures will bear interest at a rate of 10% per annum and mature one year from the first closing date of the Debenture Financing. Hepalink may elect to convert the principal amount of the Debentures and accrued and unpaid interest thereon into common shares of the Company at a conversion price equal to the lesser of CAD$0.93 per share and the 5-day volume weighted average trading price of the common shares on the date of conversion. The Company has agreed to grant Hepalink a security interest in all of its assets, including its patents and other intellectual property, as security for its obligations under the Debentures. In addition, Hepalink will receive an aggregate of 300,000 common share purchase warrants exercisable for a period of four years from the first closing date of the Debenture Financing at a price of CAD$0.93 per share (the “Warrants”). The completion of the Debenture Financing is subject to satisfaction of customary conditions for a transaction of this nature, including the approval of the Toronto Stock Exchange. The Company plans to complete the Debenture Financing by issuing the Debentures and Warrants to Hepalink in two equal tranches, with the first tranche scheduled to be completed upon satisfaction of all closing conditions in the next three days and the second tranche to be completed by May 31, 2021. The Company has a total of 238,766,021 common shares issued and outstanding. Hepalink holds 85,286,524 common shares and 11,466,619 common share purchase warrants which represents 35.72 percent of the common shares outstanding before giving effect to any outstanding warrants and 38.67 percent of the outstanding common shares assuming the exercise by Hepalink of its warrants. After giving effect to the Debenture Financing, in the event of conversion of the principal amount of the Debentures at a price of CAD$0.93, Hepalink would hold 37.78 percent of the common shares outstanding before giving effect to any outstanding warrants and 40.62 percent of the outstanding common shares assuming the exercise by Hepalink of its warrants. The net proceeds of the Debenture Financing will be used to fund research and development activities, including but not limited to, clinical trial activities, general and administrative expenses, working capital needs and other general corporate purposes. The subscription for the Debentures and Warrants by Hepalink is a related party transaction within the meaning of applicable Canadian securities laws as Hepalink is an insider of the Company. The subscription by Hepalink is exempt from the formal valuation and minority approval requirements applicable to related party transactions on the basis that the value of the transaction insofar as it involves a related party is less than 25 percent of the Company's market capitalization. About Resverlogix Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). Follow us on: Twitter: @Resverlogix_RVXLinkedIn: https://www.linkedin.com/company/resverlogix-corp-/ For further information please contact: Investor RelationsEmail: ir@resverlogix.comPhone: 403-254-9252Or visit our website: www.resverlogix.com This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information related to the Debenture Financing, including the terms of the Debenture Financing, the completion of the Debenture Financing and the use of proceeds therefrom, and the potential role of apabetalone in the treatment of patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
- GlobeNewswire
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
Apabetalone treatment was associated with a 52% hazard reduction for MACE events such as CVD death and Heart Failure, compared to placeboCALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “Novel Therapeutic Options for Cardiovascular Disease with CKD”. The publication can be viewed HERE, and the accompanying editorial HERE. “To my knowledge this is the first time that a cardiovascular risk reducing intervention – apabetalone – has shown such an improvement in clinical outcomes in patients with chronic kidney disease (CKD) – defined as an estimated glomerular filtration rate of less than 60 mL/min/1.7m2 – in a randomized placebo-controlled double-blind trial; and this is also the first time that an epigenetic modulator in the form of an oral pill has been studied in CKD,” stated Dr. Kam Kalantar-Zadeh of the University of California Irvine, member of the BETonMACE Clinical Steering Committee, and lead author of the paper. “In a prespecified analysis of the BETonMACE study, patients with CKD experienced significantly fewer major adverse cardiovascular events when treated with apabetalone compared to placebo. These data warrant further clinical research and development of apabetalone in patients with high-risk CKD.” In an editorial published alongside the new research, Dr. Carmine Zoccali, and Dr. Francesca Mallamaci, Nephrology Division, Grande Ospedale Metropolitano, Reggio Calabria, Italy, contextualized these new findings, emphasizing the unmet clinical need for patients suffering from diabetes and CKD, and highlighting the potential of apabetalone to benefit this group. “All in all, apabetalone seems to be endowed with a peculiar cardiovascular protection in patients for CKD,” wrote Dr. Zoccali and Dr. Mallamaci in the editorial. “The pronounced reduction in MACE seen in BETonMACE CKD patients highlights the potential benefit these patients could receive from apabetalone treatment,” said Donald McCaffrey, President and CEO of Resverlogix. “Patients with CKD, type-2 diabetes and established cardiovascular disease will be the primary target patient population for our upcoming registration-enabling study, BETonMACE2.” Publication Highlights include: In a pre-specified analysis in patients with CKD, participants in the placebo group with CKD experienced double the incidence of MACE (defined as cardiovascular death, nonfatal myocardial infarction, stroke, and hospitalization for congestive heart failure) than those without CKDApabetalone treatment was associated with a 52% hazard reduction for MACE events such as CVD death and Heart Failure, compared to placebo (p=0.03); early and progressive separation in events occurred between the two groupsA statistically significant reduction in alkaline phosphatase, a reported risk marker for CKD, was observed in patients with CKD after 24 weeks of apabetalone treatment (p=0.004)In addition, fewer serious adverse events were also observed in the apabetalone treated group compared to placebo (p=0.02) Publication Background and Conclusions: Chronic Kidney Disease is associated with a high burden of cardiovascular disease and poor clinical outcomes despite current standard of care treatment options. This prespecified analysis illustrated that treatment with apabetalone, in patients with stage 3 or worse CKD, diabetes and a recent acute coronary syndrome, was associated with a lower incidence of MACE. This finding demonstrates that apabetalone may offer a safe and effective treatment option for this high-risk group of patients. Previously reported BETonMACE details can be found using the following LINK. About Resverlogix Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). Follow us on: Twitter: @Resverlogix_RVXLinkedIn: https://www.linkedin.com/company/resverlogix-corp-/ For further information please contact: Investor RelationsEmail: ir@resverlogix.comPhone: 403-254-9252Or visit our website: www.resverlogix.com This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information related to the Company’s registration-enabling study – BETonMACE2 – and the potential role of apabetalone in the treatment of patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
- GlobeNewswire
Zenith Epigenetics Announces Clinical Collaboration with Astellas
To Evaluate the Combination of ZEN-3694 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate CancerCALGARY, Alberta, April 22, 2021 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a clinical stage biotechnology company focused on the development of novel epigenetic combination therapies for the treatment of cancers, announces it has entered into an agreement with Astellas Pharma Inc. (“Astellas”) to evaluate ZEN-3694, Zenith’s leading BET inhibitor, in combination with Astellas and Pfizer’s androgen receptor inhibitor, XTANDI (enzalutamide), in patients with metastatic castration resistant prostate cancer (mCRPC). Under the terms of the agreement, Zenith will sponsor and conduct a Phase 2b randomized study to evaluate the efficacy of the combination of ZEN-3694 and enzalutamide relative to single agent enzalutamide in mCRPC patients who have progressed on a prior androgen receptor signaling inhibitor (ARSi). Astellas will supply enzalutamide for the trial and Zenith will retain all rights to ZEN-3694. The clinical study is expected to start in Q2 2021. “We are delighted to collaborate with Astellas to continue the development of ZEN-3694 in combination with enzalutamide in mCRPC patients, who are resistant to an ARSI,” said Donald McCaffrey, President and Chief Executive Officer of Zenith. “Data from our recently executed single arm Phase 1b/2a study has shown that the aforementioned combination may prolong radiographic progression free survival (rPFS) in mCRPC patients and particularly in a subset of patients who had a poor response to prior ARSi and whose tumors had low androgen receptor signaling activity. There is a significant unmet need in mCRPC patients who are ARSi resistant and their current treatment options only include chemotherapy with considerable side effects. We are looking forward to validating our initial clinical findings with this well-designed randomized study.” About prostate cancer Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide. Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen action has been a mainstay for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone the treatment of prostate cancer patients has evolved rapidly over the past ten years with second generation ARSIs. Despite these advances, many patients with mCRPC fail or develop resistance to existing treatments, leading to low survival rates. About Zenith Zenith Capital Corp. is a biotechnology investment company originally spun out of Resverlogix Corp. (TSX: RVX) in 2013. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for: mCRPC in combination with androgen receptor inhibitor, XTANDI, with Astellas and Newsoara as collaboratorsTriple Negative Breast Cancer in combination with the PARP inhibitor TALZENNA with Pfizer as a collaboratorAndrogen receptor independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI with University of California, San Francisco as a collaborator For further information, please contact:Investor Relations & Communications Zenith EpigeneticsPhone: 587-390-7865Email: info@zenithepigenetics.com Website: www.zenithepigenetics.com This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the Company’s upcoming Phase 2b randomized study to evaluate the efficacy of the combination of ZEN-3694 and enzalutamide relative to single agent enzalutamide in mCRPC patients who have progressed on a prior ARSi, the Company’s development of ZEN-3694 and its potential role in the treatment of cancer and other disorders. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. Zenith disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
